-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Regeneron and its partner Roche have new phase III clinical data to show that they can treat sick patients and protect people who have not been vaccinated.
REGEN-COV consists of two monoclonal antibodies casirivimab and imdevimab.
In November 2020, REGEN-COV was granted an emergency use authorization (EUA) by the US FDA.
But REGEN-COV also faces competition from Eli Lilly's antibody cocktail.
Roche and Regeneron emphasized the relevance of the latest clinical trial results to protect high-risk populations from COVID-19 and emerging virus variants.
An investigator of the trial, Suraj Saggar, director of infectious diseases at the Holy Name Medical Center in Teaneck, New Jersey, said in a statement, “Because there are still so many people infected, and recent data show that REGEN-COV is treating The ability of new variants, these data emphasize the need to quickly adopt REGEN-COV as the standard of care to provide high-risk patients with the best opportunity to reduce serious consequences such as hospitalization or death.
Regeneron said that the company expects REGEN-COV to reach US$260 million in sales in the US market in the first quarter of this year.
In the cooperation between Regeneron and Roche, Regeneron is responsible for the development and commercialization of the US market, while Roche is responsible for markets outside the US.
However, given that the supply of vaccines will increase significantly in the next few months, is there still a need for COVID-19 treatments globally? Dr.
Currently, other clinical trials of REGEN-COV are being conducted around the world, including a Phase 3 trial for the treatment of hospitalized COVID-19 patients in the UK, and a preventive trial in the family members of COVID-19 patients to test REGEN- The therapeutic and protective effects of COV.
Reference source: Regeneron, Roche COVID-19 antibody cocktail slashes hospitalizations and tackles variants in phase 3